@article{20.500.13003/20976,
year = {2024},
month = {5},
url = {https://hdl.handle.net/20.500.13003/20976},
abstract = {Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown.
EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of <45% or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for HF outcomes.
Over a median follow-up of 17.9 months, the risk for first HF hospitalization and total HF hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events; hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P=0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P=0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P<0.05).
Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT04509674.},
publisher = {American Heart Association},
title = {Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial},
doi = {10.1161/CIRCULATIONAHA.124.069217},
journal = {Circulation},
volume = {149},
author = {Hernandez, Adrian F and Udell, Jacob A and Jones, W Schuyler and Anker, Stefan D and Petrie, Mark C and Harrington, Josephine and Mattheus, Michaela and Seide, Svenja and Zwiener, Isabella and Amir, Offer and Bahit, M Cecilia and Bauersachs, Johann and Bayes-Genis, Antoni and Chen, Yundai and Chopra, Vijay K and A Figtree, Gemma and Ge, Junbo and G Goodman, Shaun and Gotcheva, Nina and Goto, Shinya and Gasior, Tomasz and Jamal, Waheed and Januzzi, James L and Jeong, Myung Ho and Lopatin, Yuri and Lopes, Renato D and Merkely, Béla and Parikh, Puja B and Parkhomenko, Alexander and Ponikowski, Piotr and Rosselló, Xavier and Schou, Morten and Simic, Dragan and Steg, Philippe Gabriel and Szachniewicz, Joanna and van der Meer, Peter and Vinereanu, Dragos and Zieroth, Shelley and Brueckmann, Martina and Sumin, Mikhail and Bhatt, Deepak L and Butler, Javed},
}